Involvement  ||| S:0 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
pituitary  ||| S:15 E:25 ||| JJ
tumor  ||| S:25 E:31 ||| NN
transforming  ||| S:31 E:44 ||| VBG
gene  ||| S:44 E:49 ||| NN
1  ||| S:49 E:51 ||| CD
in  ||| S:51 E:54 ||| IN
psoriasis ||| S:54 E:63 ||| NN
,  ||| S:63 E:65 ||| ,
seborrheic  ||| S:65 E:76 ||| JJ
keratosis ||| S:76 E:85 ||| NN
,  ||| S:85 E:87 ||| ,
and  ||| S:87 E:91 ||| CC
skin  ||| S:91 E:96 ||| NN
tumors  ||| S:96 E:103 ||| NNS
Accumulating  ||| S:103 E:116 ||| JJ
evidence  ||| S:116 E:125 ||| NN
suggests  ||| S:125 E:134 ||| VBZ
that  ||| S:134 E:139 ||| DT
pituitary  ||| S:139 E:149 ||| JJ
tumor  ||| S:149 E:155 ||| NN
transforming  ||| S:155 E:168 ||| VBG
gene  ||| S:168 E:173 ||| NN
1  ||| S:173 E:175 ||| CD
( ||| S:175 E:176 ||| -LRB-
PTTG1 ||| S:176 E:181 ||| NNP
)  ||| S:181 E:183 ||| -RRB-
is  ||| S:183 E:186 ||| VBZ
a  ||| S:186 E:188 ||| DT
potential  ||| S:188 E:198 ||| JJ
biomarker  ||| S:198 E:208 ||| NN
for  ||| S:208 E:212 ||| IN
cancer  ||| S:212 E:219 ||| NN
malignancy  ||| S:219 E:230 ||| NN
and  ||| S:230 E:234 ||| CC
a  ||| S:234 E:236 ||| DT
cell-cycle  ||| S:236 E:247 ||| JJ
regulatory  ||| S:247 E:258 ||| JJ
protein ||| S:258 E:265 ||| NN
.  ||| S:265 E:267 ||| .
This  ||| S:267 E:272 ||| DT
investigation  ||| S:272 E:286 ||| NN
was  ||| S:286 E:290 ||| VBD
performed  ||| S:290 E:300 ||| VBN
to  ||| S:300 E:303 ||| TO
address  ||| S:303 E:311 ||| VB
the  ||| S:311 E:315 ||| DT
subcellular  ||| S:315 E:327 ||| JJ
localization  ||| S:327 E:340 ||| NN
of  ||| S:340 E:343 ||| IN
PTTG1  ||| S:343 E:349 ||| NNP
and  ||| S:349 E:353 ||| CC
its  ||| S:353 E:357 ||| PRP$
possible  ||| S:357 E:366 ||| JJ
involvement  ||| S:366 E:378 ||| NN
in  ||| S:378 E:381 ||| IN
proliferative  ||| S:381 E:395 ||| JJ
skin  ||| S:395 E:400 ||| NN
diseases ||| S:400 E:408 ||| NNS
.  ||| S:408 E:410 ||| .
In  ||| S:410 E:413 ||| IN
vitro  ||| S:413 E:419 ||| JJ
primary-cultured  ||| S:419 E:436 ||| JJ
keratinocytes  ||| S:436 E:450 ||| NN
and  ||| S:450 E:454 ||| CC
skin  ||| S:454 E:459 ||| NN
samples  ||| S:459 E:467 ||| NNS
from  ||| S:467 E:472 ||| IN
psoriasis ||| S:472 E:481 ||| NN
,  ||| S:481 E:483 ||| ,
seborrheic  ||| S:483 E:494 ||| FW
keratosis  ||| S:494 E:504 ||| FW
( ||| S:504 E:505 ||| -LRB-
SK ||| S:505 E:507 ||| NNP
) ||| S:507 E:508 ||| -RRB-
,  ||| S:508 E:510 ||| ,
basal  ||| S:510 E:516 ||| JJ
cell  ||| S:516 E:521 ||| NN
carcinoma  ||| S:521 E:531 ||| NNS
( ||| S:531 E:532 ||| -LRB-
BCC ||| S:532 E:535 ||| NNP
) ||| S:535 E:536 ||| -RRB-
,  ||| S:536 E:538 ||| ,
and  ||| S:538 E:542 ||| CC
squamous  ||| S:542 E:551 ||| JJ
cell  ||| S:551 E:556 ||| NN
carcinoma  ||| S:556 E:566 ||| NNS
( ||| S:566 E:567 ||| -LRB-
SCC ||| S:567 E:570 ||| NNP
)  ||| S:570 E:572 ||| -RRB-
were  ||| S:572 E:577 ||| VBD
investigated  ||| S:577 E:590 ||| VBN
by  ||| S:590 E:593 ||| IN
immunofluorescence  ||| S:593 E:612 ||| NN
and  ||| S:612 E:616 ||| CC
real-time  ||| S:616 E:626 ||| JJ
PCR ||| S:626 E:629 ||| NNP
.  ||| S:629 E:631 ||| .
In  ||| S:631 E:634 ||| IN
normal  ||| S:634 E:641 ||| JJ
skin ||| S:641 E:645 ||| NN
,  ||| S:645 E:647 ||| ,
PTTG1  ||| S:647 E:653 ||| NNP
is  ||| S:653 E:656 ||| VBZ
localized  ||| S:656 E:666 ||| VBN
predominantly  ||| S:666 E:680 ||| RB
in  ||| S:680 E:683 ||| IN
10 ||| S:683 E:685 ||| CD
%  ||| S:685 E:687 ||| NN
of  ||| S:687 E:690 ||| IN
basal  ||| S:690 E:696 ||| JJ
keratinocytes ||| S:696 E:709 ||| NN
,  ||| S:709 E:711 ||| ,
while  ||| S:711 E:717 ||| IN
30-40 ||| S:717 E:722 ||| CD
%  ||| S:722 E:724 ||| NN
in  ||| S:724 E:727 ||| IN
basal  ||| S:727 E:733 ||| NN
and  ||| S:733 E:737 ||| CC
suprabasal  ||| S:737 E:748 ||| JJ
psoriatic  ||| S:748 E:758 ||| JJ
keratinocytes ||| S:758 E:771 ||| NN
.  ||| S:771 E:773 ||| .
PTTG1  ||| S:773 E:779 ||| NNP
mRNA  ||| S:779 E:784 ||| NNP
in  ||| S:784 E:787 ||| IN
psoriatic  ||| S:787 E:797 ||| JJ
epidermis  ||| S:797 E:807 ||| NN
is  ||| S:807 E:810 ||| VBZ
about  ||| S:810 E:816 ||| RB
5-fold  ||| S:816 E:823 ||| CD
more  ||| S:823 E:828 ||| JJR
than  ||| S:828 E:833 ||| IN
that  ||| S:833 E:838 ||| DT
in  ||| S:838 E:841 ||| IN
normal  ||| S:841 E:848 ||| JJ
one  ||| S:848 E:852 ||| CD
( ||| S:852 E:853 ||| -LRB-
P  ||| S:853 E:854 ||| NNP
< ||| S:854 E:855 ||| SYM
0.01 ||| S:855 E:859 ||| CD
) ||| S:859 E:860 ||| -RRB-
.  ||| S:860 E:862 ||| .
PTTG1  ||| S:862 E:868 ||| NNP
is  ||| S:868 E:871 ||| VBZ
localized  ||| S:871 E:881 ||| VBN
in  ||| S:881 E:884 ||| IN
cytoplasm  ||| S:884 E:894 ||| NN
in  ||| S:894 E:897 ||| IN
primary-cultured  ||| S:897 E:914 ||| JJ
normal  ||| S:914 E:921 ||| JJ
and  ||| S:921 E:925 ||| CC
psoriatic  ||| S:925 E:935 ||| JJ
keratinocytes ||| S:935 E:948 ||| NN
,  ||| S:948 E:950 ||| ,
and  ||| S:950 E:954 ||| CC
PTTG1  ||| S:954 E:960 ||| CD
in  ||| S:960 E:963 ||| IN
HaCaT  ||| S:963 E:969 ||| JJ
cells  ||| S:969 E:975 ||| NNS
is  ||| S:975 E:978 ||| VBZ
distributed  ||| S:978 E:990 ||| VBN
throughout  ||| S:990 E:1001 ||| IN
the  ||| S:1001 E:1005 ||| DT
cytoplasm  ||| S:1005 E:1015 ||| NN
of  ||| S:1015 E:1018 ||| IN
metaphase  ||| S:1018 E:1028 ||| JJ
cells ||| S:1028 E:1033 ||| NNS
.  ||| S:1033 E:1035 ||| .
PTTG1  ||| S:1035 E:1041 ||| NNP
is  ||| S:1041 E:1044 ||| VBZ
seen  ||| S:1044 E:1049 ||| VBN
at  ||| S:1049 E:1052 ||| IN
both  ||| S:1052 E:1057 ||| DT
G2  ||| S:1057 E:1060 ||| NNP
and  ||| S:1060 E:1064 ||| CC
M  ||| S:1064 E:1066 ||| NNP
phases ||| S:1066 E:1072 ||| NNS
,  ||| S:1072 E:1074 ||| ,
and  ||| S:1074 E:1078 ||| CC
highest  ||| S:1078 E:1086 ||| JJS
PTTG1  ||| S:1086 E:1092 ||| CD
expression  ||| S:1092 E:1103 ||| NN
correlates  ||| S:1103 E:1114 ||| NN
with  ||| S:1114 E:1119 ||| IN
highest  ||| S:1119 E:1127 ||| JJS
cyclin  ||| S:1127 E:1134 ||| CD
B1  ||| S:1134 E:1137 ||| CD
expression  ||| S:1137 E:1148 ||| NN
and  ||| S:1148 E:1152 ||| CC
highest  ||| S:1152 E:1160 ||| JJS
degree  ||| S:1160 E:1167 ||| NN
of  ||| S:1167 E:1170 ||| IN
nuclear  ||| S:1170 E:1178 ||| JJ
pleomorphism  ||| S:1178 E:1191 ||| NN
at  ||| S:1191 E:1194 ||| IN
M  ||| S:1194 E:1196 ||| NNP
phase ||| S:1196 E:1201 ||| NN
.  ||| S:1201 E:1203 ||| .
The  ||| S:1203 E:1207 ||| DT
positive  ||| S:1207 E:1216 ||| JJ
rate  ||| S:1216 E:1221 ||| NN
of  ||| S:1221 E:1224 ||| IN
PTTG1  ||| S:1224 E:1230 ||| CD
in  ||| S:1230 E:1233 ||| IN
SK ||| S:1233 E:1235 ||| NNP
,  ||| S:1235 E:1237 ||| ,
BCC ||| S:1237 E:1240 ||| NNP
,  ||| S:1240 E:1242 ||| ,
and  ||| S:1242 E:1246 ||| CC
SCC  ||| S:1246 E:1250 ||| NNP
is  ||| S:1250 E:1253 ||| VBZ
about  ||| S:1253 E:1259 ||| RB
10 ||| S:1259 E:1261 ||| CD
% ||| S:1261 E:1262 ||| NN
,  ||| S:1262 E:1264 ||| ,
20 ||| S:1264 E:1266 ||| CD
% ||| S:1266 E:1267 ||| NN
,  ||| S:1267 E:1269 ||| ,
and  ||| S:1269 E:1273 ||| CC
more  ||| S:1273 E:1278 ||| JJR
than  ||| S:1278 E:1283 ||| IN
80 ||| S:1283 E:1285 ||| CD
% ||| S:1285 E:1286 ||| NN
,  ||| S:1286 E:1288 ||| ,
respectively ||| S:1288 E:1300 ||| RB
.  ||| S:1300 E:1302 ||| .
PTTG1  ||| S:1302 E:1308 ||| NNP
siRNA ||| S:1308 E:1313 ||| NNP
,  ||| S:1313 E:1315 ||| ,
which  ||| S:1315 E:1321 ||| WDT
knocks  ||| S:1321 E:1328 ||| VBZ
down  ||| S:1328 E:1333 ||| RP
the  ||| S:1333 E:1337 ||| DT
expression  ||| S:1337 E:1348 ||| NN
of  ||| S:1348 E:1351 ||| IN
PTTG1 ||| S:1351 E:1356 ||| NNP
,  ||| S:1356 E:1358 ||| ,
reduced  ||| S:1358 E:1366 ||| VBD
the  ||| S:1366 E:1370 ||| DT
invasive  ||| S:1370 E:1379 ||| JJ
capacity  ||| S:1379 E:1388 ||| NN
of  ||| S:1388 E:1391 ||| IN
A431  ||| S:1391 E:1396 ||| CD
cells ||| S:1396 E:1401 ||| NNS
.  ||| S:1401 E:1403 ||| .
In  ||| S:1403 E:1406 ||| IN
conclusion ||| S:1406 E:1416 ||| NN
,  ||| S:1416 E:1418 ||| ,
PTTG1  ||| S:1418 E:1424 ||| NNP
is  ||| S:1424 E:1427 ||| VBZ
a  ||| S:1427 E:1429 ||| DT
marker  ||| S:1429 E:1436 ||| NN
for  ||| S:1436 E:1440 ||| IN
proliferative  ||| S:1440 E:1454 ||| JJ
skin  ||| S:1454 E:1459 ||| NN
diseases  ||| S:1459 E:1468 ||| NNS
associated  ||| S:1468 E:1479 ||| VBN
with  ||| S:1479 E:1484 ||| IN
cell  ||| S:1484 E:1489 ||| NN
cycle  ||| S:1489 E:1495 ||| NN
regulation  ||| S:1495 E:1506 ||| NN
and  ||| S:1506 E:1510 ||| CC
may  ||| S:1510 E:1514 ||| MD
aid  ||| S:1514 E:1518 ||| VB
in  ||| S:1518 E:1521 ||| IN
detection  ||| S:1521 E:1531 ||| NN
of  ||| S:1531 E:1534 ||| IN
aggressive  ||| S:1534 E:1545 ||| JJ
cancers ||| S:1545 E:1552 ||| NNS
.  ||| S:1552 E:1554 ||| .
